Who are MVC-COV1901's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): BNT162b2 Pfizer-BioNTech/Comirnaty, Tozinameran (BNT162b2) / Riltozinameran (BNT162b2 OMI BA.1), COMIRNATY intramuscular injection, AntiCov-220, Comirnaty Original/Omicron BA.4-5, Combination BNT162b2 and BNT162b2 OMI.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/mvc-cov1901.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

MVC-COV1901 — Competitive Intelligence Brief

MVC-COV1901 (MVC-COV1901) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Protein subunit vaccine. Area: Immunology / Infectious Disease.

phase 3 Protein subunit vaccine SARS-CoV-2 spike protein Immunology / Infectious Disease Biologic Live · refreshed every 30 min

Target snapshot

MVC-COV1901 (MVC-COV1901) — Medigen Vaccine Biologics Corp.. MVC-COV1901 is a protein subunit vaccine that stimulates immune responses against SARS-CoV-2 by presenting viral spike protein antigens to the immune system.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
MVC-COV1901 TARGET	MVC-COV1901	Medigen Vaccine Biologics Corp.	phase 3	Protein subunit vaccine	SARS-CoV-2 spike protein
BNT162b2 Pfizer-BioNTech/Comirnaty	BNT162b2 Pfizer-BioNTech/Comirnaty	KK Women's and Children's Hospital	marketed	mRNA vaccine	SARS-CoV-2 spike protein (S protein)
Tozinameran (BNT162b2) / Riltozinameran (BNT162b2 OMI BA.1)	tozinameran-bnt162b2-riltozinameran-bnt162b2-omi-ba-1	Pfizer	marketed	vaccine	SARS-CoV-2 spike protein
COMIRNATY intramuscular injection	comirnaty-intramuscular-injection	Pfizer	marketed	mRNA vaccine	SARS-CoV-2 spike protein
AntiCov-220	AntiCov-220	Nguyen Thi Trieu, MD	marketed	Monoclonal antibody	SARS-CoV-2 spike protein
Comirnaty Original/Omicron BA.4-5	Comirnaty Original/Omicron BA.4-5	Jules Bordet Institute	marketed	mRNA vaccine	SARS-CoV-2 spike protein (original strain and Omicron BA.4-5 variants)
Combination BNT162b2 and BNT162b2 OMI	combination-bnt162b2-and-bnt162b2-omi	Pfizer	marketed	mRNA vaccine	SARS-CoV-2 spike protein

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Protein subunit vaccine class)

Novavax · 2 drugs in this class
Taoyuan General Hospital · 2 drugs in this class
Medigen Vaccine Biologics Corp. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). MVC-COV1901 — Competitive Intelligence Brief. https://druglandscape.com/ci/mvc-cov1901. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab